Press Releases

The project is part of the Group’s industrial plan to support its global growth The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter The redevelopment of the facility and its surrounding area will be centered on innovation and sustainability criteria   Milan, March 27th, 2025 – Chiesi Group, a global biopharmaceutical company headquartered in Parma, Italy, has announced a major investment in Nerviano (Milan, Italy), with the construction of a new facility for the production of its therapeutic solutions. The project entails the revitalization of this historical production site, first established in 1965 as an oncology research centre for Farmitalia Carlo Erba and subsequently subjected to several ownership changes, until its closure in 2024. The facility will be primarily dedicated to manufacturing carbon minimal inhalers, reinforcing the company’s commitment to both patients’ health and sustainable healthcare solutions. Dry powder inhalers and sterile biological products will also be developed in Nerviano. The €430 million investment, spread between 2025 and 2030, will fund the redevelopment of a 124,000-square-meter industrial area, transforming it into an international center of excellence. This initiative is part of the Group’s global industrial strategy, which includes ongoing investments in its facilities in Parma (Italy) and Blois (France) and operations in Santana de Parnaíba (Brazil) to meet the growing needs of people living with respiratory conditions. The objective is to support the company’s growth and its goal of achieving Net Zero emissions by 2035.   The redevelopment will modernize the existing site, originally built in the 1980s, turning it into a next-generation production center. Once fully operational, the site will feature over 3,000 square meters of laboratory space and a photovoltaic park with an installed capacity sufficient to ensure the plant's energy self-sufficiency. Adjacent to the industrial facility, a 20,000-square-meter wooded area will undergo a regeneration project.   Beyond its environmental and technological advancements, the investment will deliver tangible benefits to the local community. The site is expected to create approximately 300 new jobs by 2029, stimulating economic growth in the region.   "We chose Nerviano for its strategic location and the potential of the industrial area, which we will transform into a center of excellence for the production of next-generation inhalers," said Giuseppe Accogli, CEO of Chiesi Group. "This investment strengthens our presence in Italy and Europe, consolidates our leadership in the sector, and creates new growth opportunities for the local community. It also complements our significant investments in the Parma area, notably our recent Biotech Center launch."     About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.     Contacts for Media:   Gruppo Chiesi Laura Vergani, Senior Vice President, Global Communications & Public Affairs e-mail: mediarelations@chiesi.com   Davide Paterlini, Global External Communications Sr. Manager mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com

Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting Chiesi's global ambitions New committees established: Governance, Nomination and Compensation; Audit and Risk; Strategy, Sustainability and Innovation   Parma, January 29th, 2025 – Chiesi, the international research-focused biopharmaceutical Group, announces the appointment of three new independent Non-Executive Directors (NEDs) to its Board: Roch Doliveux, Paolo Pucci and Daphne Quimi. Following a global search, the new Board members have joined the current five at Chiesi, effective January 28th, 2025.   The addition of three new NEDs is a significant part of Chiesi's broader strategy to enhance the Board’s capabilities, focusing on both upskilling and further internationalizing its leadership.   Driven by the continued foresight of the Chiesi family, this step represents a clear advancement in the company's efforts to enrich corporate governance as part of its ongoing international and patient impact growth. The new NEDs bring valuable expertise that will guide the company towards industry best practices.   By fostering diversity and introducing new competencies, they will support Chiesi’s commitment to sustainable growth, organizational transition, and international expansion, including into the important US market.   Furthermore, with the inclusion of these new members, Chiesi has also improved its Board functionality, particularly through the establishment of internal committees designed to enhance decision-making processes. The new committees are set up as follows: Governance, Nomination and Compensation Committee: Roch Doliveux (Chairperson), Maria Paola Chiesi, Daphne Quimi, Alessandro Chiesi Audit and Risk Committee: Daphne Quimi (Chairperson), Giacomo Chiesi, Paolo Pucci, Andrea Chiesi Strategy, Sustainability and Innovation Committee: Paolo Pucci (Chairperson), Maria Paola Chiesi, Roch Doliveux, Andrea Chiesi Each of the new Board members brings extensive experience to support Chiesi adapt to the rapidly evolving marketplace and continue its evolution:   Roch Doliveux has extensive leadership experience in Biopharmaceuticals and was CEO of UCB for ten years. He chairs the Boards of Pierre Fabre SA and Oxford Biomedica.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ArQule, leading it until its acquisition by Merck & Co. in 2020, and he held senior roles at Bayer Schering Pharma. He serves on the Boards of Replimune Group, Merus and West Pharmaceutical Services.   Daphne Quimi has made significant contributions to the pharmaceutical industry.  As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. She also held senior roles at Johnson & Johnson, Bristol-Myers Squibb and Avon. She serves on the Boards of Amylyx Pharmaceuticals and Century Therapeutics.   “We are thrilled to welcome Roch Doliveux, Paolo Pucci, and Daphne Quimi to our Board”, says Alessandro Chiesi, Chair. “Their experiences will enhance Chiesi’s governance and support our global ambitions. In line with our family’s vision, this move further reflects our commitment to constant improvement, and will allow us to even better focus on the strategic drivers of our company. It will benefit the Group as we continue to grow and internationalize, and we look forward to the positive impact they will bring.”   “I am confident Roch, Paolo, and Daphne will be excellent additions to the Chiesi Board,” says Giuseppe Accogli, CEO. “They all bring extensive international experience and diverse expertise, which will enhance our competitiveness. Their fresh perspectives and valuable skills will enrich our Board discussions, and strengthen our governance framework, which will help to unlock our potential to improve and develop as a company.”   About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.   For further information please visit www.chiesi.com   About the new Non-Executive Directors: Roch Doliveux has driven innovation and growth in healthcare through various leadership roles. He facilitated collaboration in medical research as Chairman of the Innovative Medicines Initiative and GLG Institute Healthcare. His previous NED roles included UCB and Stryker (USA). Currently, he chairs the Boards of Pierre Fabre Group and Oxford Biomedica, where he continues to contribute to advancing healthcare and mental health initiatives. Doliveux is a Swiss national.   Paolo Pucci has had a distinguished career in the pharmaceutical industry. He served as CEO of ARQULE, leading it until its acquisition by Merck & Co. in 2020. At Bayer Schering Pharma, he held senior roles, including President of Global Oncology. His tenure at Eli Lilly included leadership positions in Sweden and Italy. Pucci also has extensive NED experience, serving on the Boards of companies like Merus NV, Tarus Therapeutics, and Replimune Group. Pucci is a dual US-Italian national.   Daphne Quimi has made significant contributions to the pharmaceutical industry. As CFO at Amicus Therapeutics, she oversaw IT and facilities during its international expansion. With 13 years at Johnson & Johnson, she gained extensive experience in audit, FP&A, and reporting. She serves on the boards of Amylyx Pharmaceuticals and Century Therapeutics, playing key roles in IPOs, acquisitions and CEO transitions. Quimi is a US national.

Chiesi is the only European pharmaceutical company and the first Italian company ever to be included in the World’s Best Workplaces™ The accolade reflects Chiesi's dedication to people’s well-being, continuous improvement, and creating a positive work environment Chiesi was also recently ranked in in the Best Workplaces in Europe™ 2024, Best Workplaces for Women™ in Greater China, and UK's Best Workplaces in BioPharma™, among others   Parma (Italy) November 14, 2024 – Chiesi Group, an international biopharmaceutical company focused on research, has been named one of the 25 World’s Best Workplaces™ in 2024 by Great Place To Work® (GPTW) and Fortune magazine, ranking 23rd on this year’s list. This is the first time that Chiesi has been included in the GPTW global list, standing out as the first Italian company ever to achieve this honor. Headquartered in Parma, Italy, the Group has 31 affiliates worldwide and employs over 7,000 people, 56% of whom are women. More than 1,300 employees are dedicated to R&D.   “We are immensely proud to be the only European pharmaceutical company included in the World's Best Workplaces™ rankings. Being part of such a selective global list of only 25 companies is a source of huge motivation for continuous improvement.” said Giuseppe Accogli, Chief Executive Officer, Chiesi Group. “This placement stems from our firm commitment to our people's well-being, as it reflects their direct feedback and contribution in shaping Chiesi into a place where we all enjoy working. I believe this accolade will further increase our sense of pride and belonging to a company fully dedicated to serving patients around the world in everything we do”.   Great Place To Work® and Fortune’s annual list selects 25 global organizations that participated in Great Place To Work’s employee survey process, with 7.4 million responses received, representing 20 million employees worldwide. To be considered for the list, companies must be identified as outstanding global employers with recognition on at least five Best Workplaces™ lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2023 or early 2024.   Reacting to the result, Giacomo Mazzariello, Chief Human Resources Officer, said, “Our talented global team is the cornerstone of our success. In all our locations around the world, we strive to create an environment where our people feel that Chiesi is their 'Happy Place'. We believe in human-centered leadership, and we are committed to make every voice matter. We strive for every team member to feel empowered to make a difference by bringing their authentic selves to work, implementing policies aiming at a concrete experience of work-life balance, or as we call it, (work-) Life Harmony. From closing the gender pay gap to fostering a culture of well-being and innovation, we’re not just achieving a ranking; we’re working towards an even brighter future. We are aiming to make a stronger, lasting impact together with our existing talents, and the new ones that will join us over time”.   In addition to today’s recognition, in 2024 Chiesi was also ranked as one of the top 10 Best Workplaces in Europe™, and it was recognized by Fortune as one of the Great Places to Work in Biopharma in the U.S., Best Workplaces for Women™ in Greater China, UK's Best Workplaces in BioPharma™, and UK's Best Workplaces for Development™, among other accolades.   About the Fortune World’s Best Workplaces™ Great Place To Work selected the World’s Best Workplaces by gathering and analyzing more than 7.4 million confidential survey responses, representing the experiences of 20 million employees worldwide at Great Place To Work Certified organizations. Organizations are assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. Companies must have appeared on at least five Best Workplaces lists in Asia, Europe, Latin America, Africa, North America, or Australia during 2023 or early 2024, and have at least 5,000 employees worldwide, with 40% outside of its headquartered country.  Read the full methodology.To be considered, all companies use the Great Place To Work Trust Index™ survey.   To learn more about the Best Workplaces in Europe™ list click here.   About Chiesi Group Chiesi is research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

Chiesi Group is making a strategic investment of €400 to establish its new Biotech Center of Excellence in Parma. The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development and autonomous production capacity. Chiesi’s strategy aligns with EU priorities on innovation, security, and private R&D investment.     Parma (Italy), 30th September 2024 - Today, Chiesi Group, an international biopharmaceutical company focused on research, celebrates the operational launch of its Biotech Center of Excellence. This state-of-the-art facility is dedicated to developing and producing monoclonal antibodies, enzymes, and other proteins.   This facility is anticipated to be outstanding in Europe for its integrated approach, housing the entire supply chain under one roof. From the production of drug substances from mammalian cells to their transformation into drug products and final packaging, everything will be done in a single location. The new site’s seamless integration of research and industrial production capabilities will be a major advantage, enabling more efficient transitions from development to manufacturing and significantly enhancing Chiesi’s ability to innovate and bring new treatments to market.    This adaptability ensures Chiesi will remain at the forefront of medical trends, while the Center’s capability will support the production of small and large batches, and both experimental and approved drugs to facilitate a seamless transition from clinical trials to commercial manufacturing. The new center will enhance Chiesi’s focus areas in respiratory, special care treatments, and rare diseases, thereby strengthening its overall strategic position.    To be more and more competitive in today’s pharmaceutical landscape, Chiesi is placing a strong emphasis on innovation. The decision to establish a center of excellence to produce biologic drugs in Italy is even more significant in the context of Mario Draghi’s report on European competitiveness. The report underscores the urgency of closing the innovation gap with the US and China by focusing on upskilling, research, and development, and addressing regulatory hurdles.   The Biotech Center of Excellence will help address healthcare challenges, aiming for a more resilient and sustainable system. Chiesi seeks to align with recent biopharmaceutical advancements, and increase production in Europe, attracting international talent and investment, and creating global partnerships. This project supports Chiesi’s growth in R&D, with over 20% of turnover allocated to it, making Chiesi a leader in R&D investment among Italian pharmaceutical companies.    “Today, we inaugurate a center with a production site that projects us into a new path of care, allowing us to continue making a difference in serving people and families living with chronic diseases, especially rare diseases, with increasingly innovative technologies. In a rapidly changing world, this facility will help generate new knowledge and skills, contributing to a national biotech supply chain that attracts and retains the best global talents”, said Alessandro Chiesi, Chiesi Group Chair.   “At Chiesi, innovation is at the heart of everything we do. The opening of our new Biotech Center marks a bold leap forward in our commitment to delivering groundbreaking therapies that truly transform patients' lives. This center will elevate our production capabilities to new heights and reinforce our dedication to driving innovation. More than that, it will empower us to forge powerful collaborations and push the boundaries of what’s possible in patient’s care”, said Giuseppe Accogli, CEO at Chiesi.    Today’s event celebrated Chiesi’s dedication to research in Italy, highlighting ongoing investments that create value and high-quality jobs. Of the approximately €400 million that Chiesi will invest, €120 million is allocated to infrastructure, while €260 million will be spent over the long term (2023–2030) on materials, innovative technologies, skills development, and training.   The Center of Excellence will employ up to 200 specialists, with current technical activities involving 60 people, expected to grow to over 80 by the end of 2025. The new therapeutic opportunities from the Biotech Center will position Chiesi as a major player in the rapidly growing biopharmaceutical sector.

At the 2024 European Respiratory Society Congress (ERS), Chiesi Group will convene two symposia to highlight the importance of patient centricity in managing asthma and COPD Chiesi Group will present the value for patients in using innovative decentralized elements in clinical trial design, with positive findings regarding the potential to decrease patient burden and increase accessibility Building on recent investments, Chiesi Group will share key progress in its carbon minimal inhaler project, including positive study results and the initiation of a Phase 3 clinical trial   VIENNA, September 4, 2024 – Chiesi Group, an international, research-focused biopharmaceuticals group, is pleased to participate in the ERS Congress 2024, which is being held from 7 to 11 September in Vienna, Austria. The ERS Congress is an annual event that brings together the world’s respiratory experts to showcase the latest advances in respiratory medicine and science.   Giuseppe Accogli, CEO of Chiesi Farmaceutici S.p.A, said, “At Chiesi, we recognize the critical link between a healthy planet and healthy lungs. The climate crisis disproportionately affects people with chronic respiratory diseases. Chiesi is committed to developing innovative treatments that benefit both people and the environment, focusing on engaging patients as well as the healthcare and scientific communities."   Sponsoring patient-centric symposia   As part of its commitment to the care and improvement of the quality of life of people suffering from respiratory diseases, such as asthma and COPD, Chiesi is proud to be welcoming leading experts at two company-sponsored symposia. They will provide important scientific insights on patient perspectives for the management of these diseases:   ‘Holistic approach to improve quality of life of people living with COPD’, 8 September at 12:15. With experts from Switzerland, Germany, Italy and the UK, this symposium will provide a high scientific and patient-centric perspective on the real needs and challenges patients face in their daily lives. It will also present relevant recent evidence from real world data in terms of the effectiveness and benefits of triple inhaled therapy for COPD patients.     ‘Embrace patient perspectives and new real-world evidence towards better asthma management’, 9 September at 12:45. Convening expert presentations in combination with an insightful interview between an asthma patient and a practicing respiratory physician, this symposium will open with an exploration of the role of Small Airways Disease (SAD) in asthma, revealing its significant impact on exacerbations, lung function and quality of life. Exploring the importance of patients as partners in diagnosing and understanding their disease, it will further seek to understand how the burden on patients can be reduced in clinical trials, while better leveraging real world evidence studies to improve understanding of patient needs and how to address them.     Chiesi is also hosting two institutional presentations at its booth within the ERS Congress: ‘Clearing the Air: An Industry Response to Preserve Patients' and Planet's Health’, 10 September 2024 at 12:15. ‘Innovation in Chiesi clinical trials to deliver patient and site focused research’, 10 September 2024 at 13:00.     Patient insights into decentralization of a clinical trial in asthma (TANGO)   Chiesi Group continues to advance asthma and COPD treatment with an inhaled, non-steroidal anti-inflammatory treatment which addresses significant unmet needs in these conditions and is being tested through an extensive and geographically widespread clinical program including 2 pivotal Phase 3 studies in COPD and a Phase 2 study in asthma. The latter, called TANGO, represents an important milestone for the company in its effort to reinforce patient-centricity throughout the steps of development.   As the trial continues to enroll, Chiesi presents findings from a qualitative research study conducted in asthma patients in 4 countries, exploring the TANGO design presented as a hypothetical trial. Findings from the study point to positive acceptance of decentralized approaches when clearly explained and may support reduced patient burden and expanded trial accessibility.   At the ERS Congress, Chiesi will present a poster entitled ‘Patient insight into decentralization of a clinical trial in asthma (TANGO)’ on 10 September from 8:00 to 9:30.   “We are proud that Chiesi is transforming its commitment to patient-centricity into action by utilizing innovative trial tools, such as digitalization and decentralization, through our TANGO clinical trial. In a context where industry leaders are striving to drive increased accessibility and diversity in clinical trials, we will continue to promote approaches that not only reduce the burden on patients but also ensure inclusion and accessibility,” commented Diego Ardigò, Head of Research & Development at Chiesi Group.     Key developments in Carbon Minimal Inhaler Project   Recognising that climate change and health are inextricably connected[1], with the worsening of one, leading to the more severe symptoms in health[2], Chiesi will share key developments in its carbon minimal inhaler project at the ERS Congress. This is an important step in its journey to achieve Net Zero greenhouse gas emissions by 2035, while preserving asthma and COPD patients’ needs.    “Chiesi is committed to transforming its decades-long leadership in respiratory care into cutting-edge and innovative solutions for patients. Our reach extends from pioneering trial designs and sustainable devices to enhanced care pathways, digital innovations, and exploring new indications through strategic partnerships. We are forging a unique path toward achieving comprehensive global leadership in the respiratory care sector,” said Michelle Soriano, Head of Respiratory Franchise (AIR) at Chiesi Group.     The company is proceeding with a long-term phase 3 clinical trial for the new carbon minimal inhalers platform[3], replacing the current hydrofluorocarbon propellant (HFC 134a) with a new, low global warming potential one (HFC 152a). Chiesi has already completed two short-term clinical studies assessing the safety of the new propellant[4] and pharmacokinetics studies on the new carbon minimal fixed double and triple combinations[5],[6]. These studies collectively provided reassuring evidence of a similar performance, safety and tolerability of the new formulations, when compared to the current one, enabling a seamless and safe transition for patients and healthcare systems while significantly reducing environmental impact.   At the ERS Congress, Chiesi will present a poster entitled, ‘Sustaining treatment for asthma and COPD patients while minimizing carbon footprint: effect of HFA-152a and HFA-134a on normal lung mucociliary clearance’ on 10 September from 8:00 to 9:30.     Improvements in respiratory healthcare delivery   Chiesi values its role as an industry partner of the International Respiratory Coalition (IRC) to support engagement with national healthcare systems and the implementation of best practices globally for improved respiratory outcomes. At the ERS Congress, the IRC will host a special session to explore the role of team contributions in respiratory healthcare delivery.     Asthma and COPD Awareness Campaign   Chiesi will also showcase the real lives of asthma and COPD patients in a campaign at the Congress, around Vienna and on social media. Stories of determination and courage in overcoming the limitations imposed by these diseases will, therefore, reach both healthcare professionals and the general public with the aim of generating greater awareness, understanding and empathy.   About the European Respiratory Society ERS is one of the leading medical organisations in the respiratory field, with a growing membership spanning over 160 countries. ERS prioritises science, education and advocacy in order to promote lung health, alleviate suffering from disease and drive standards for respiratory medicine globally.   About Chiesi Group Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.   By adopting the legal from of Benefit Corporation in Italy, the US and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses committed to continuously measure and improve their social and environmental performance. The company has committed to reach Net-Zero greenhouse gases (GHG) emissions by 2035.   With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide and counts more than 7,000 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK and Sweden.   Contacts for the press:   Carla Arrieta Martinez  Head of Global External Communication & Media Relations  Tel: +39 340 8879754  Email: c.arrieta@chiesi.com       Ryan Murray Director, FTI Consulting Tel: +32 477 563565 Email: ChiesiMedia@fticonsulting.com   References [1] https://pubmed.ncbi.nlm.nih.gov/25244362/ [2] https://pubmed.ncbi.nlm.nih.gov/25244362/ [3] Clinical Trials.Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) (TRECOS). Available from: https://clinicaltrials.gov/study/NCT06264674 [4] Clinical Trials. Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance. Available from: https://clinicaltrials.gov/study/NCT05875025; Clinical Trials. Study to Compare the Effects of Two Propellants in Adults With Mild Asthma. Available from: https://clinicaltrials.gov/study/NCT05472662 [5] https://www.chiesi.com/en/carbon-minimal-inhalers-milestone/ [6] https://doi.org/10.1016/j.pupt.2024.102299

Chiesi Group's Sustainability Report 2023 highlights impacts on strategic areas such as Patients, Planet, People and Prosperity while anticipating regulatory changes. Patients: Chiesi invested 23.8% of its revenues in research and development and advocated for patients with respiratory conditions, emphasizing the health impacts of air pollution. Planet: Chiesi is progressing towards its goal of Net Zero greenhouse gas emissions by 2035 with a detailed Climate Transition Plan. In 2023, the company earned a Platinum medal in the EcoVadis sustainability assessment. People: Chiesi introduced Global Parenthood Guidelines to contribute to gender equality and increased corporate volunteering hours by 77.5%. Prosperity: Chiesi distributed 77% of the economic value generated to stakeholders—including the local community, capital providers, public administration, employees, collaborators, suppliers, and vendors.   Parma, July 22nd, 2024 – Chiesi, an international research-focused biopharmaceutical group, announces the release of its 2023 Sustainability Report, now available at www.chiesi.com. The report is organized in four key sections: Patients, Planet, People and Prosperity.   Chiesi's business approach is rooted in creating shared value by integrating societal challenges into its core mission. At the end of 2023, Chiesi merged its Shared Value & Sustainability and Global Strategy functions with key cross-functional departments, including Global Business Development, Competitive Intelligence, SKAI (Scientific and External Knowledge Analytics and Insights), COI&C (Center for Open Innovation and Competence), and Digital Health. This new integrated department is named "Strategy, Sustainability, and Growth Unit."   «Uniting these departments and their diverse skills and perspectives, we're pioneering a transversal approach to drive the company's future economic evolution and sustainable growth», shares Siham Imani, the new Head of the Strategy, Sustainability, and Growth Unit. «Through this integrative governance, we utilize our collective expertise to innovate and foster positive societal and environmental impact». PATIENTS – Advancing Innovation and Health Equity to Meet Patient Needs Chiesi’s mission is to develop and market innovative therapeutic solutions that enhance people’s quality of life. In 2023, driven by innovation, the Group invested €720.8 million—23.8% of sales (over €3 billion)—in Research and Development. Chiesi was once again recognized as the leading Italian pharmaceutical company for patents filed at the European Patent Office, with a portfolio of over 6,200 global patents.   In 2023, Chiesi advanced the construction of the Group's Biotech Center of Excellence, set to open in fall 2024. This facility will focus on the development and production of biological medicines, managing the entire process from cell cultivation to drug manufacturing and packaging for global distribution. The initiative aims to attract top talent, enhance Italy's specialized expertise, and strengthen Europe's leadership in biotechnological innovation.   Chiesi introduced a unified Patient Journey Framework to promote a culture of continuous patient engagement and needs assessment, recognizing the unique experience of each patient throughout their care journey. This approach considers the specific aspects of their diseases, the national health systems, and collaboration with physicians.   Aligned with the UN Agenda 2030, Chiesi is working on a Health Equity strategy to reach more patients and improve the standard of care for those living with diseases by addressing gaps in healthcare access. Nearly all Chiesi affiliates now have active projects aimed at achieving health equity.   PLANET – Climate Transition Plan: Achieving Net Zero by 2035 Chiesi is committed to fighting climate change, aiming to achieve Net Zero greenhouse gas (GHG) emissions by 2035. The Group has adopted a robust Climate Transition Plan ahead of the anticipated regulatory requirements of the Corporate Sustainability Reporting Directive (CSRD). This plan serves as a strategic roadmap to meet emission reduction targets and ensures long-term resilience and adaptability in addressing climate-related challenges.   In 2023, compared to our baseline year of 2019, Chiesi achieved a 39% reduction in Scope 1[1] and 2[2] GHG emissions. While our Scope 3 emissions have increased alongside company growth, Chiesi is investing over €350 million in developing a new pressurized metered dose inhaler (pMDI). This initiative aims to slash the current product carbon footprint by 90% by substituting the current propellant with a low global warming potential alternative. Following the completion of two short-term clinical trials to assess the safety of the new propellant, the Group initiated a long-term Phase III clinical safety trial in November 2023. Chiesi targets completing the primary clinical development of its Carbon Minimal pMDI portfolio, utilizing the low GWP propellant HFA 152a, by 2025.   The value chain is crucial in Chiesi’s path to achieving Net Zero by 2035. The Code of Interdependence, co-developed with strategic partners, guides the conduct of suppliers, partners, and distributors. Chiesi has begun implementing EcoVadis as a primary tool to evaluate its suppliers' environmental and social performance, earning itself the EcoVadis Platinum Medal[3] in 2023.   PEOPLE – Prioritizing Wellbeing, Equality, and Community Development Chiesi prioritizes employees’ wellbeing and fosters a positive, respectful work environment. This commitment is underscored by certifications like "Great Place to Work" (GPTW) and "Top Employer."   Through initiatives promoting equal opportunities, fair compensation, and supportive policies, the Group aims to ensure all employees are rewarded equitably. After closing the gender pay gap in 2022, Chiesi became the first Italian pharmaceutical company certified for Gender Equality by Bureau Veritas.   In 2023, Chiesi launched programs to achieve equal career progression for all genders by 2030. These include mentoring programs for women and Global Parenthood Guidelines supporting modern families, with flexible work policies, training for new parents, equitable and extended parental leave, and economic and childcare support.   Recognizing the importance of community health to business success, Chiesi's corporate volunteering program engaged over 2,000 employees (30.5% of the workforce), totaling 16,656 hours—an increase of 77.5% from 2022.   PROSPERITY – Do Good, Do Well, Repeat Demonstrating our commitment to social and environmental responsibility, in 2023 Chiesi distributed 77% of the economic value generated to stakeholders - including the local community, capital providers, public administration, employees, collaborators, suppliers, and vendors. The remaining 23% was reinvested into the company to foster long-term growth.   «At Chiesi, we believe in the principle of 'Do good, do well, repeat.' This philosophy underscores our commitment to creating successful business solutions that benefit society, and reinvesting in impactful initiatives» says Maria Paola Chiesi, Vice Chair at Chiesi Group. «Through continuous innovation and strategic reinvestment, we aim to create a ripple effect of positive change, demonstrating that doing good and doing well are not only compatible but mutually reinforcing».   Chiesi's 2023 Sustainability Report has voluntarily undergone an external assurance process in compliance with the Global Reporting Initiative (GRI). GRI is an independent international standards organization that helps businesses understand and communicate their impacts on Environmental, Social, and Governance (ESG) issues. In response to the new European Corporate Sustainability Reporting Directive, Chiesi Group is committed to enhancing its data collection and reporting processes, giving equal importance to financial and sustainability reporting, and ensuring they are aligned and integrated.   Chiesi: Shaping a Sustainable Legacy and Future Vision «Chiesi is a family-owned company with a history stretching back almost 90 years. This legacy gives us a unique ability to plan for the long term and it addresses the challenges facing current and future generations», says Giuseppe Accogli, CEO of the Group. «On this journey, our aim is not to stand out as a singular entity. Instead, we recognize that effectively addressing the challenges of the future necessitates a collaborative effort among companies, regulators, and suppliers within our industry».   Chiesi has strategically approached sustainable change in recent years. Last year, the company introduced an ambitious Sustainability Strategic Plan spanning 2023-2028, serving as a comprehensive roadmap. Previously, Chiesi Group adopted the legal form of Benefit Corporation (in 2018 in Italy and the U.S.; in 2021 in France) and became a certified B Corp (2019), making environmental, social, and economic sustainability growth drivers of its business development.     [1] Scope 1: indicates direct GHG emissions from sources owned or controlled by the reporting company. [2] Scope 2: indicates indirect GHG emissions associated with the purchase of electricity or energy for heating and cooling the buildings. [3] Chiesi Achieves Platinum Medal from EcoVadis: https://www.chiesi.com/en/media-hub/news/medal-ecovadis